Compare BMHL & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BMHL | RCEL |
|---|---|---|
| Founded | 2016 | N/A |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.2M | 102.5M |
| IPO Year | 2025 | N/A |
| Metric | BMHL | RCEL |
|---|---|---|
| Price | $3.73 | $3.91 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.17 |
| AVG Volume (30 Days) | 5.0K | ★ 228.3K |
| Earning Date | 01-30-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9.50 | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | $6,873,097.00 | ★ $72,401,000.00 |
| Revenue This Year | N/A | $13.12 |
| Revenue Next Year | N/A | $27.56 |
| P/E Ratio | $69.06 | ★ N/A |
| Revenue Growth | ★ 66.02 | 20.59 |
| 52 Week Low | $2.72 | $3.22 |
| 52 Week High | $4.49 | $11.25 |
| Indicator | BMHL | RCEL |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 66.13 |
| Support Level | N/A | $3.24 |
| Resistance Level | N/A | $3.57 |
| Average True Range (ATR) | 0.00 | 0.20 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 0.00 | 95.83 |
Bluemount Holdings Ltd through its operating subsidiaries, it is a Hong Kong-based consulting and advisory and financial services provider, as well as trader of commodities such as luxury timepieces. The financial services includes underwriting and placing services, securities dealing and brokerage services, and asset management services. It provides comprehensive consulting and advisory services on business development strategies to its diverse clientele. Generally, the company provides consulting and advisory business for the following segments: Corporate Finance; and Strategic Communications.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.